Kosuke Iwasaki

• Developing health technology assessments, including cost-effectiveness, cost-utilization, and cost-benefit analysis for pharmaceutical companies and medical device companies
• Assessing the economic value of drugs, including antihypertensive and anti-hyperlipidemic agents, diabetes drugs, hepatitis C drugs, antidepressants, anticancer agents, anticoagulation drugs, and drugs for COPD, hemophilia, and amyotrophic lateral sclerosis
• Assessing the economic value of bariatric surgery
• Assessing the economic value of disease management programs and screening
• Conducting analyses on adverse drug events for hospitals
• Developing value-based designs of health insurance, including the cost-sharing structure of diabetes drugs and chemotherapy for cancer patients
• Developing a predictive model for a disease management company in Japan
• Developing a predictive model for long-term care cost
• Developing budget impact models for drugs for diabetes and hepatitis C patients
• Developing benchmarks on outcomes for hospitals
• Conducting stochastic modeling, including Generalized Linear models, Survival models, Hierarchal Bayesian models, and Bayesian Network models
• Developing healthcare reform models for accountable care organizations
• Developing health insurance products, disability income products, long-term care products, and critical illness products for life and health insurance companies
• Conducting pricing and profit testing of insurance policies
• Performing due diligence in M&A of life/health insurance companies

He is a member of the Institute of Actuaries of Japan’s Health Insurance Committee.